

Issue #52: October 2012

This publication announces formulary policy changes at Capital Health. If physicians and healthcare professionals require background information on new formulary policies approved for Capital Health they should direct their inquiries to the Drug Information Centre (see contact information below).

Effective October 2012

The following policies were approved by the District Medical Advisory Committee (Apr11) on the recommendation of the District Drugs and Therapeutics Committee (Mar11).

ADDITIONS TO FORMULARY	
Fosfomycin	<p><i>Monurol®</i></p> <p>Fosfomycin is an antibacterial used for the treatment of multidrug resistant urinary tract infections. Fosfomycin is bactericidal in urine at therapeutic doses. It has a broad spectrum of activity against aerobic gram positive and negative organisms, especially <i>E.coli</i>, <i>Pseudomonas aeruginosa</i>, <i>Proteus</i>, <i>Providencia</i>, <i>Serratia</i>, <i>Klebsiella</i>, <i>Citrobacter</i>, <i>Enterococcus</i>, and <i>Enterobacter</i> including multi-drug resistant strains. The advantage of fosfomycin is infrequent dosing and it is the only oral agent effective against multi drug resistant organisms. There is generally no cross resistance between fosfomycin and other classes of bacterial agents such as beta lactams and aminoglycosides.</p> <p>Fosfomycin was approved by the District Medical Advisory Committee as well as the District Drugs and Therapeutics Committee in the spring of 2011. However, it has only become available on the Canadian market as of September 2012.</p>

The information contained in this newsletter may also be accessed online at:

<http://cdhaintra/departmentservices/pharmacy/Formulary/index.cfm>

Published by the Pharmacy Department, Capital Health
Editor: Natasha Rodney, B. Sc. (Pharm.)
Drug Information
Tel: (902) 473-8503
Email: Natasha.rodney@cdha.nshealth.ca